6533b86cfe1ef96bd12c8a6e
RESEARCH PRODUCT
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?
Marc PeetersGiovanni SortinoNicola SilvestrisDaniele FanaleMarta CastigliaFrancesco PassigliaGiuseppe BronteAntonio GalvanoChristian RolfoGiuseppe CiceroAntonio GiordanoAntonio GiordanoAntonio RussoViviana Bazansubject
OncologyNeuroblastoma RAS viral oncogene homologmedicine.medical_specialtyColorectal cancerDrug ResistanceCetuximabAntineoplastic AgentsReviewGene mutationCetuximab; Colorectal cancer; Epidermal growth factor receptor; Panitumumab; RAS; Oncologymedicine.disease_causeAntibodiesGTP PhosphohydrolasesProto-Oncogene Proteins p21(ras)Internal medicineMonoclonalmedicinePanitumumabHumansEpidermal growth factor receptorLiquid biopsyNeoplasm MetastasisBiologyneoplasmsbiologyCetuximabEpidermal Growth FactorEpidermal growth factor receptorPanitumumabAntibodies MonoclonalMembrane Proteinsmedicine.diseaseCetuximab; Colorectal cancer; Epidermal growth factor receptor; Panitumumab; RAS; Antibodies Monoclonal; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Drug Resistance Neoplasm; GTP Phosphohydrolases; Humans; Membrane Proteins; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Receptor Epidermal Growth Factor; OncologyColorectal cancerErbB ReceptorsOncologyDrug Resistance NeoplasmMutationCancer researchbiology.proteinNeoplasmHuman medicineKRASColorectal Neoplasmsmedicine.drugReceptorRASdescription
Abstract: Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti-EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-07-22 |